title: Pulmonary arterial hypertension in connective tissue diseases.
abstract: Pulmonary arterial hypertension (PAH) is an entity that is known to complicate connective tissue diseases (CTD). PAH in CTD is a very important diagnosis which greatly affects treatment and prognosis. The most commonly affected CTD is scleroderma, although lupus, inflammatory myopathies such as poly and dermatomyositis, and mixed CTD are also associated with PAH. The manifestations of PAH have both similarities and differences when occurring in the setting of CTD as compared with idiopathic PAH. These differences are most notable in scleroderma. In this section we will discuss the features of PAH as they appear in CTDs, and in particular, scleroderma. The focus of this article is an approach to the diagnosis and treatment of PAH in CTD, and how this setting might differ from idiopathic and other forms of PAH.
authors.affiliation: North Shore-LIJ Health System, Lake Success, NY 11042, USA. augoldbe@lij.edu
authors.forename: Avram
authors.initials: A
authors.lastname: Goldberg
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077300:Bosentan; D003240:Connective Tissue Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D065128:Endothelin Receptor Antagonists; D011464:Epoprostenol / Q000819:agonists; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology*; D010666:Phenylpropionates / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D011724:Pyridazines / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D010666:Phenylpropionates; D058986:Phosphodiesterase 5 Inhibitors; D011724:Pyridazines; D013449:Sulfonamides; D011464:Epoprostenol; C467894:ambrisentan; D000077300:Bosentan